6533b83afe1ef96bd12a6fc0
RESEARCH PRODUCT
Molecular imaging of gastroenteropancreatic neuroendocrine tumors.
Matthias MiedererChristian FottnerMatthias M. Webersubject
medicine.medical_specialtyPathologyNeuroendocrine tumorsScintigraphylaw.inventionConfocal microscopylawmedicineHumansReceptors SomatostatinGastrointestinal NeoplasmsMicroscopy Confocalmedicine.diagnostic_testbusiness.industrySomatostatin receptorGastroenterologyPet imagingmedicine.diseaseCarcinoma NeuroendocrineMolecular ImagingPancreatic NeoplasmsNeuroendocrine TumorsSomatostatinPositron emission tomographyPositron-Emission TomographyRadiologyMolecular imagingRadiopharmaceuticalsbusinessdescription
Somatostatin-receptor scintigraphy has become an obligatory molecular imaging method in the management of patients with neuroendocrine tumors when metastatic disease is suspected. Using positron emission tomography and new somatostatin analogues, sensitivity of somatostatin receptor imaging has further increased. With a combination of morphologic imaging methods, such as hybrid imaging by PET/CT, this method represents the method of choice in many centers and efforts are under way to translate somatostatin receptor imaging onto a cellular level by endoscopic confocal microscopy. Other clinically relevant functional pathways in neuroendocrine tumors that are accessible by PET imaging are glucose metabolism and amine precursor uptake and decarboxylation.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-11-25 | Gastroenterology clinics of North America |